RT Journal
T1 NEw and nonofficial drugs
JF Journal of the American Medical Association
JO Journal of the American Medical Association
YR 1959
FD July 11
VO 170
IS 11
SP 1316
OP 1317
DO 10.1001/jama.1959.63010110010012a
UL http://dx.doi.org/10.1001/jama.1959.63010110010012a
AB Valethamate Bromide (Murel).— 
    2-Diethylaminoethyl 3-methyl-2-phenylvalerate methylbromide.— The structural formula of valethamate bromide may be represented as follows:Actions and Uses.— 
    Valethamate bromide, introduced in 1958, is a quaternary ammonium compound which is used clinically as an antispasmodic. Animal experiments indicate that the drug acts predominantly as an anticholinergic agent. In addition, it exerts a mild direct inhibiting effect on the motility of smooth muscle. Valethamate is also said to exhibit a transient ganglionic blocking action; such effects are minimal, if not imperceptible, in the doses used clinically. The drug does not diminish gastric secretion to any appreciable extent.Valethamate bromide is proposed for oral and parenteral use for the treatment of hypermotility and spasm of the gastrointestinal, genitourinary, and biliary tracts as well as for the adjunctive management of peptic ulcer. Although favorable results have been reported in some patients, the bulk of the clinical evidence available to date is